James Marion

James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.
Ballard Power Systems Inc. (USA) (NASDAQ:BLDP)

Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) Gets Bump from Tech, Orders

Ballard Power Systems Inc. (USA) (NASDAQ:BLDP)

Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) shares jumped 27% after the provider of clean energy solutions unveiled a new lightweight fuel cell that uses less platinum. The company announcing a backlog order of $264 million also appears to have triggered investor interest in the stock.

Investors Reaction

Wednesday’s rally was the biggest in more than a year, allowing the stock to achieve a new 52-week high of $4.75 a share. The rally also capped a fine run, which began late last month, which has seen the stock add more than 4% in market value.

Ballard Power Systems Inc. (USA) (NASDAQ:BLDP)
One month BLDP stock price chart

Renewed investor on Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) comes on growing confidence for the positive impact the new fuel cell technology could have on the company. Up until now, fuel cell systems have hard to contend with substantial amounts of platinum which makes them extremely expensive.

Ballard Power’s new system details the use of far less precious metals which will result in an 80% decline in the amount of platinum required. According to the vice president of technology and product development, Kevin Colbow, the new Non-Precious Metal Catalysts NPMC design should be ready for use before the end of the year.

“The NPMC-based FCgen®-1040 stack represents a step-change in PEM fuel cell technology with high performance at a reduced cost. Since platinum contributes 10-to-15% of the cost of a fuel cell stack today, we are very excited about the potential cost savings NPMC technology can enable moving forward,” said Dr. Colbow.

Ballard Power Systems collaborated Nisshinbo Holdings to come up with the NPMC-based proton exchange membrane. The two are currently exploring various commercial applications of the new technology.

Growing Order Book

Separately, Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) says its order backlog totaled $263.5 million as of June 30, 2017, representing the actual value of orders that customers have made a contractual commitment for. The company’s 12-month Order Book stood at $97.2 million as of June 30, 2017.

According to the Chief Executive Officer, Randall MacEwen, the strong order backlog and 12-month order book numbers underscores the company’s continued growth trajectory. The company will be hosting an Investor and Analysts Day event, where it plans to provide more information and insight on how it plans to deliver on the commitments over the next 12 months.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BLDP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Tremor Video Inc. (NYSE:TRMR)

Tremor Video Inc. (NYSE:TRMR) Rebrands To Telaria Inc.

Tremor Video Inc. (NYSE:TRMR)

Tremor Video Inc. (NYSE:TRMR) shares rose 2.30% after the video software monetization company announced plans to change its name to Telaria Inc. as part of a rebranding strategy.  In addition to the name change, the company also released a new corporate logo and brand platform as part of the updated strategy.

Tremor Video Rebranding

The proposed changes are geared towards transforming Tremor Video Inc. (NYSE:TRMR) into a fully programmatic software platform for premium video partners. Telaria will also position itself to be a data-enriched platform that is able to monetize and manage video inventory with the speed, control, and transparency.

Tremor Video will trade under ticker name Tremor Video Inc (NYSE:TRMR) until market close on September 25, 2017, after which the company is to trade under the name Telaria Inc. and ticker symbol TLRA.

Investors reacted positively to the proposed rebranding by sending the stock to an all-time high for the year. The stock is currently trading close to its 52-week high of $4.10 a share as it continues to trade in a strong uptrend that began last month. Tremor Video Inc (NYSE:TRMR) is up by more than 50% for the year after over performing the overall industry.

According to the chief marketing officer, Jennifer Catto, the rebranding push underscores Tremor Video dynamism and leadership role in the video industry. According to the executive, the name change supports a belief that advertising technology needs to be fast and frictionless to attract clients.

“With our platform’s unparalleled speed, diagnostic capabilities, and complete pricing transparency, our publisher clients have never been better positioned to unlock the full value of their video content,” said CEO, Mark Zagorski.

Trade Desk Rebranding

The rebranding push comes after Tremor Video Inc (NYSE:TRMR) announced deeper integration with Trade Desk Inc. The integration will result in the company offering curated access to premium programmatic Connected Television (CTV) and Over The Top (OTT) advertising inventory. Dish, Sling, and Bloomberg Media have already made some of their premium inventory available.

Changing consumer habits continue to drive rapid growth on CTV and OTT, presenting opportunities that Tremor Video plans to take advantage of. According to research firm eMarketer, CTV users increased 20.6% last year to account for 56% of U.S population. The finding is a testament that more people are watching digital video on connected TVs.

“We are excited to work with The Trade Desk to help advertisers understand the value of CTV, and how to reach the 18-34-year-old audience that is leading the shift from traditional TV to IP enabled programming,” said Katie Evans, COO of Tremor Video Inc (NYSE:TRMR).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TRMR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Ophthotech Corp (NASDAQ:OPHT)

Ophthotech Corp (NASDAQ:OPHT) Lower On AMD Drug and Partnership Concerns

Ophthotech Corp (NASDAQ:OPHT)

Ophthotech Corp (NASDAQ:OPHT) shares declined 14.52% after Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) said its drug for vision loss did not meet its primary endpoint in clinical trials. The ripple effect comes on the heels of the biopharmaceutical company also announcing that a Phase 3 trial of its main candidate drug for the condition, Fovista, failed to meet primary endpoints in two trials.

Opthotech Stock Performance

Last week’s sell-off brought to an end August bullish run that saw the stock add about 7.4 in market value. The stock is currently trading in a strong downtrend in a $2.59-$3.11 trading range. The stock has underperformed the overall industry after shedding more than 90% in market value since the start of the year.

A study of Fovista for the treatment of age-related macular degeneration turned out to be a disappointment as no statistical significance was observed with the drug combination. Disappointing clinical trials have been the biggest undoing for Ophthotech Corp (NASDAQ:OPHT) – thus fuelling a sell-off wave that has pushed the stock from highs of $40 a share to current lows of $2.65.

Following two successive disappointing clinical trials, investors have already started to question the future of an ongoing collaboration with Novartis AG (ADR) (NYSE:NVS).

Ophthotech Corp (NASDAQ:OPHT)
One month OPHT stock price chart

Novartis Agreement Uncertainty

Novartis has already suspended a large part of the agreement that touched on the commercialization of the drug outside the U.S. The giant drug maker insists that the AMD drug will have to prove itself in clinical trials if the licensing agreement is to hold.

Concerns that Novartis could pull away from the deal continues to fuel the sell-off of Ophthotech Corp (NASDAQ:OPHT) stock. Such a move could be catastrophic given that the company derives a good chunk of its revenues from milestones and other payments from collaborations.

Collaborations revenue declined 94% in the recent quarter to $1.7 million – an indication of how things could turn sour if Novartis pulls the plug. Ophthotech Corp (NASDAQ:OPHT) reported a net loss of (-$0.62) a share or the second quarter narrower than a net loss of (-$1.07) a share that analysts were expecting. The company exited the quarter with cash and cash equivalent of $196 million which is sufficient to fund operations over the next 12 months.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPHT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Cash Reserve Up $34 Million After Rights Offering

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) traded lower after the developer of exoskeleton solutions said it raised $34 million in a previously announced rights offering. Puissance Capital Management invested $20.5 million for 20,536,058 common shares. The stock was down by 1.71% on the news.

Stock Performance

The stock is currently trading in a downtrend in a $1.02 – $1.17 trading range, levels last seen in June. Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) faces the risk of being hit with a delisting notice by the NASDAQ Capital market after the stock fell below the $1 a share mark. A close below the current trading range could see the stock registering a new 52-week low.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
One month EKSO stock price chart

Ekso Bionics develops and sells exoskeleton for use in the healthcare, industrial, and military industries. The company’s lead product is the Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) GT, a bionic suit designed to provide the ability to walk over ground without the need for a cane or crutches.

According to the Chief Executive Officer, Thomas Looby, the closure of the $34 million rights offering provides additional resources to enhance the development and commercialization of exoskeleton solutions,.

“We believe that this financing reflects growing excitement within the investment community for the potential of our products and technologies. The capital raised through this financing will provide us with additional resources to further advance the adoption and development of our innovative exoskeleton solutions,” said Mr. Looby.

Net Proceeds Use

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) plans to use part of the net proceeds to accelerate the adoption of its exoskeleton solutions in the rehabilitation market as it also moves to expand its footprint into China. The funds will also be used for further research, development, and commercialization.

A $20 Million investment by Puissance Capital demonstrates the global asset management firm’s confidence in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s long-term prospects. Following the investment, Ted Wang of Puissance will join the Ekso Board of Directors.

Separately, Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has confirmed the appointment of Christian Babini as the new vice president of sales for the America’s. He joins the company with more than 20 years of diverse medical device sales experience. He previously served as the Global Vice-President for sales and marketing development at Medtech Surgical.

“[..] Ekso’s innovative exoskeleton portfolio provides significant value to our customers, and I look forward to helping accelerate our sales effort and expand our market presence,” said Mr. Babini

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EKSO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Amedica Corporation (NASDAQ:AMDA)

Is Amedica Corporation (NASDAQ:AMDA) Proposed Reverse Stock-Split Dead?

Amedica Corporation (NASDAQ:AMDA)

Amedica Corporation (NASDAQ:AMDA) gained over 1.00% after adjourning, for a second time, a special stockholders meeting. The company is seeking to get shareholder approval on a proposed reverse stock-split as it seeks to shore up its share price. Failure to secure enough votes needed left the company with no choice but to adjourn the meeting as it continues to solicit for additional votes.

Amedica Corporation (NASDAQ:AMDA)
One month AMDA stock price chart

NASDAQ Delisting Notice

A move to carry out a reverse stock split comes on the heels of Amedica Corporation (NASDAQ:AMDA) shares slumping to all-time lows, having been under immense selling pressure for the better part of the year. The stock is the subject of a delisting notice by the NASDAQ on failing to meet the minimum bid requirement of $1 a share.

Amedica is currently pushing for hearing before the NASDAQ Hearings Panel to discuss the necessary steps it is undertaking to meet the minimum listing requirements for continued listing in the exchange. Pending the hearings determination, the company will continue trading in the exchange.

Reverse Stock Split

The stock is in dire need of new catalysts to bounce back from the current trading levels and regain NASDAQ compliance. The management had proposed a reverse stock-split to help shore up the stock price. The company needs to garner approval of a majority of all outstanding shares if any reverse stock-split is to come into effect.

Amedica Corporation (NASDAQ:AMDA) has since pushed the special stockholder’s meeting to September 21, 2017 as it moves to lobby them on the need to approve the proposed reverse split.

“During the period of the adjournment, Amedica will continue to solicit proxies from its stockholders. Stockholders who have not already done so are encouraged to vote — because passage of the proposal requires a majority of outstanding shares to vote in favor, unvoted shares have the same effect as shares voted against,” Amedica Corporation (NASDAQ:AMDA) in a statement.

Amedica Corporation (NASDAQ:AMDA) is a commercial stage biomaterial company that develops, manufactures and sells a range of medical devices based on a proprietary silicon nitride ceramic technology platform. The company also develops wear and corrosion resistant implant components for hip and knee arthroplasty.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AMDA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Lightbridge Corp (NASDAQ:LTBR)

Lightbridge Corp (NASDAQ:LTBR) Partners with AREVA NP

Lightbridge Corp (NASDAQ:LTBR)

Lightbridge Corp (NASDAQ:LTBR) and AREVA NP have signed a binding agreement for the development and commercialization of a new line of advanced metallic fuel for nuclear plants. Investors reacted to the news by sending the stock up 7.4%.

Wednesday’s rally did little to reverse a strong selling pressure that has plagued the stock in recent weeks. The stock had initially gapped to highs of $1.40 a share before it slumped, to end the day at $1.20 a share. Lightbridge Corp (NASDAQ:LTBR) faces immediate resistance at $1.40, above which it could rise to highs of $2.00 a share – last seen in June.

Lightbridge Corp (NASDAQ:LTBR)
One month LTBR stock price chart

 

Lightbridge-AREVA Joint Venture

The signing of the agreement for the formation of the joint venture comes after six months of intense negotiations focusing on international legal and regulatory complexities. The joint venture should be up and running early next year after the signing of an operating agreement.

Lightbridge Corp (NASDAQ:LTBR) and AREVA have agreed that cash and non-cash contributions into the joint venture will be equal as ownership is on a 50-50 basis. The two companies are currently negotiating agreement on Intellectual property and research and development. Lightbridge has already received a Notice of Allowance in South Korea for a key division patent covering its innovative metallic file assembly design.

Joint Venture Functions

The JV is to act as an exclusive vehicle through which Lightbridge and AREVA are to collaborate on the development, demonstration, licensing and marketing of nuclear fuel assemblies. The venture will encompass pressurized water reactors, boiling water reactors, research reactors and Light water-cooled small-and medium sized reactors. `

“This innovative fuel design offers significant benefit to the nuclear energy industry and efforts are well underway to bring it to market. To achieve this goal, AREVA NP and Lightbridge are engaging our vast worldwide infrastructure, our innovative spirits and, most importantly, our experience,” said Gary Mignogna AREVA CEO.

Lightbridge Corp (NASDAQ:LTBR) has already started to conduct preparatory work for the fabrication and irradiation testing of metallic fuel samples at its Halden research reactor in Norway. The company is also working with leading U.S nuclear utilities as it seeks to gain valuable feedback on the development of its fuel technology.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LTBR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Amfil Technologies Inc (OTCMKTS:AMFE)

Amfil Technologies Inc (OTCMKTS:AMFE) Targets Cannabis Opportunities

Amfil Technologies Inc (OTCMKTS:AMFE)

Amfil Technologies Inc (OTCMKTS:AMFE) fell 5.07% after announcing that its subsidiary is in the process of finalizing roll-out plans for a 14,000 sq. ft. Canadian facility. The company is also fresh from announcing plans to reduce its share count by 300 million shares as it seeks to narrow the gap between authorized and outstanding share count.

The stock is currently trading in an upward trend having retreated from this year’s high of $0.23 a share. However, a recent sell-off wave threatens to push the stock lower after breaking a key support level at the $0.18. The stock faces immediate support at the $0.09 mark below which it could fall to $0.06 per share – just above this year’s lows of $0.01 a share.

Amfil Technologies Inc (OTCMKTS:AMFE)
One month AMFE stock price chart

Share Reduction

Amfil Technologies Inc (OTCMKTS:AMFE) is in the process of reducing the number of authorized shares from 900 million to 600 million as it seeks to shore up its market cap. The reduction should be complete by the end of the month. The company remains optimistic that starting Q3 2018, profits will be used to fund expansion plans instead of having to rely on stock issuance.

The reduction also underscores the company’s commitment to strengthening current shareholders value as the transaction will reduce stock dilution which should enhance investor confidence.

“The Company continues to move ahead with the recently announced acquisition of the cloud-based franchising software company and future acquisitions may potentially be done so by way of preferred stock to further this initiative,” Amfil Technologies Inc (OTCMKTS:AMFE) in a statement.

Cannabis Business

Separately, Amfil Technologies Inc (OTCMKTS:AMFE) continues to gain traction in pursuit of growth opportunities in the legal cannabis business. The company’s EcoPrO3 GRO3 Antimicrobial Systems as well as Roto-Gro Hydroponic Systems continue to elicit strong demand from a number of companies that are in the cannabis production business.

The company’s GR03 subsidiary is currently furnishing a quotation request received last month from a client who is planning to venture into the cannabis production business. A Roto-Gro representative is also working round the clock to provide the customer with an estimated number of units needed for a double stack roll-out at the 14,000 sq. facility.

In addition, Amfil Technologies Inc (OTCMKTS:AMFE)’s Snakes and Lattes subsidiary has also embarked on an expansion drive this time focusing on the South-East Asia and European markets. The tabletop gaming bar and café unit has already received orders from clients in the new markets.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AMFE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Bellerophon Therapeutics Inc (NASDAQ:BLPH)

What Happened to Bellerophon Therapeutics Inc (NASDAQ:BLPH) Shares?

Bellerophon Therapeutics Inc (NASDAQ:BLPH)

Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) jumped 4.42% after the firm announced positive results in a mid-stage trial of INOpulse, a novel treatment for pulmonary hypertension patients with chronic obstructive disease PH-COPD. Clinical trial results indicate that INOpulse inhaled nitric oxide met its primary and secondary trial endpoints.

Bellerophon Therapeutics Inc (NASDAQ:BLPH)
One month BLPH stock price chart

Positive INOpulse Trial Results

Prior to the positive clinical trial results, Bellerophon Therapeutics Inc (NASDAQ:BLPH) had been trading in a range from highs of $1.98 a share to lows of $1.00 a share. Tuesday’s price action saw the stock rally to highs of $1.25 a share before retreating to the $1.18 mark. The stock faces immediate resistance at the $1.60 a share mark above which it could surge to this year’s high of $1.98 a share.

Positive INOpulse trial results has helped strengthen investor confidence on the stock especially after the company reported second quarter earnings that failed to meet expectations.

INOpulse inhaled nitric oxide demonstrated significant improvement in six-minute walking distance and blood vessel volume in the Phase 2 trial. The therapy was also well tolerated with no safety concerns in all the test subjects.

“Collectively, these Phase 2 data demonstrate the promising potential of INOpulse to safely deliver pulsatile nitric oxide in a targeted manner to achieve medically and statistically significant improvements in exercise capacity and hemodynamics,” said Dr. Raymond L. Benza of the Cardiovascular Institute at Allegheny General Hospital.

INOpulse Prospects

The positive Phase 2 trial results builds on previous acute studies that showed INOpulse has the potential to act as a first-in-class therapy. Bellerophon Therapeutics Inc (NASDAQ:BLPH) CEO, Fabian Tenenbaum, believes the therapy has the potential to provide targeted vasodilation to ventilated areas of the lungs. The executive also remains confident on the therapy becoming an effective treatment for the more than 700,000 PH-COPD patients in the U.S

Bellerophon Therapeutics Inc (NASDAQ:BLPH) is currently conducting phase 3 trial on INOpulse as it tries to investigate its ability to act as a novel treatment for Pulmonary Arterial Hypertension. Trial results on the ongoing study should be out sometime next year.

Development on the use of INOpulse to treat various cardiovascular conditions has helped shrug off investor concerns especially after Bellerophon Therapeutics Inc (NASDAQ:BLPH) posted a (-$3.9) million Q2 net loss.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BLPH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

iPass Inc. (NASDAQ:IPAS) Partners with Mobilcom-Debitel

iPass Inc. (NASDAQ:IPAS)

iPass Inc. (NASDAQ:IPAS) has teamed up with software and managed services provider, Mobilise, to provide a new global Wi-Fi service to mobilcom-debitel customers. IPAS stock traded lower in Friday’s trading session in response to the news, as short sellers continue to position themselves for lower prices.

Stock Performance

A bullish run on iPass Inc. (NASDAQ:IPAS) stock that began in March ended as the stock failed to break through a key resistance level at the $1.50 mark. The stock has since gapped lower from the $1.20 mark and is currently trading near all-time lows.

A decline in investor sentiments on iPass Inc. (NASDAQ:IPAS) has seen the stock trade in a tight $0.51 – $0.57 trading range as it closes in on its 52-week low of $0.51 a share. Positive investor views on the stock are being challenged by a slowdown in the adoption of the company’s new technology and erosion in pay-per-use business continues to compound the issue.

iPass Inc. (NASDAQ:IPAS)
IPAS one month stock price chart

Net Loss- Outlook

iPass Inc. (NASDAQ:IPAS) reported a net loss of (-$5.3) million for the second quarter as revenue came in at $13.5 million. A further indication of a slowdown in the company’s business is a new revenue guidance of $54 million, down from a previous guidance of between $69 million and $73 million. A net loss guidance of between (-$4.5) million and (-$2) million also continues to rattle investors.

“While continuing to achieve progress toward our strategy and goals in the longer term, our performance in the second quarter was disappointing, reflecting delays in execution and timing driven by three significant factors that impacted revenue,” said Gary Griffiths, president, and CEO.

Mobilise Collaboration Synergies

iPass SmartConnect software’s development kit underperformed in the second quarter in terms of revenue generation. The company attributes the poor performance to insufficient technical support and engineering resources to address disparate requirements that emerged during the roll outs. Strategic partners requiring longer evaluation and deployment cycles also affected revenue generation.

A collaboration with Mobilise to provide Wi-Fi services on mobilcom-debitel network should have a positive impact on iPass SmartConnect SDK going forward. Mobilise has agreed to provide the Wi-Fi solution using iPass SmartConnect SDK.

The new Wi-Fi service seeks to enhance connectivity options to mobilcom-debitel 12 million mobile subscribers. The independent German telecommunications company plans to use the collaboration to further enhance connectivity experience of its customers.

“This contract with mobilcom-debitel is further validation of the unique value proposition Mobilise and iPass are bringing to the market,” said iPass Inc. (NASDAQ:IPAS) chief commercial officer Patricia Hume.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IPAS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

On The Move Systems Corp (OTCMKTS:OMVS)

On The Move Systems Corp (OTCMKTS:OMVS) Completes Acquisition, Drops 10%

On The Move Systems Corp (OTCMKTS:OMVS)

On The Move Systems Corp (OTCMKTS:OMVS) traded lower after announcing it had completed the acquisition of Robotic Assistance Devices (RAD). The stock was down by 10.58% in Thursday’s trading session, to end the day at $0.169 a share.

Stock Performance

On The Move Systems Corp (OTCMKTS:OMVS) has been on an impressive run ever since it announced plans to acquire Robotic Assistance Devices. The stock had rallied to highs of $0.27 a share and traders waiting to see if the recent pull back is just a minor correction.

A point of concern is that the stock is currently trading at the lower end of its $0.17 – $0.22 trading range. The stock faces immediate support at the $0.14 level. It now awaits to be seen if the acquisition of RAD will continue to strengthen investor’s sentiments on the company’s long term prospects.

On The Move Systems Corp (OTCMKTS:OMVS)
One month OTCMKTS:OMVS stock price chart

Robotic Assistance Devices is already strengthening On The Move Systems Corp (OTCMKTS:OMVS) revenue base having received a commitment for 62 robots with a reported contract value of $6 million. The unit has also signed two purchase order contracts with major companies. The company is banking on its sales pipeline of over 50 fortune 500 companies, and 25 dealers and distributors, to attract more deals for its robotic solutions.

“I look forward to working together with OMVS and having the opportunity to build RAD into a major player in the robotic guard market. We have made great progress to date and with the close of this acquisition we will be well positioned to accelerate our development and deliver significant growth milestones in the near future,” said Steve Reinharz, President, and CEO of RAD.

Romeo Power Collaboration

Robotic Assistance has entered into an agreement with Romeo Power to outfit its SMP Robotics Security Guard Robot with the firm’s lithium ion energy solution. Integration of Romeo’s Power battery solutions should allow RAD’s robots to provide up to 12 hours of continuous operations.

The collaboration also paves way for Romeo Power to deploy two S5 autonomous security guard robots at its headquarters in Vernon Calif.

On The Move Systems Corp (OTCMKTS:OMVS) has also signed a distribution agreement with one of the largest security companies in North America for the distribution of the RAD’s autonomous security robots. The agreement should assist the company in penetrating the North American market.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OMVS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.